Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In Conversation with Tony Letai.

Eleni Skourti1, Anthony Letai2,3

  • 1The FEBS Journal Editorial Office, Cambridge, UK.

The FEBS Journal
|November 1, 2021
PubMed
Summary

Professor Anthony Letai

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

What does BCL-2 do? From new molecular insights to the clinical implications.

Cell death and differentiation·2026
Same author

Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Cell death and differentiation·2025
Same author

Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma.

Leukemia·2025
Same author

Apoptotic priming in senescence predicts specific senolysis by quantitative analysis of mitochondrial dependencies.

Cell death and differentiation·2025
Same author

Senolysis by ABT-263 is associated with inherent apoptotic dependence of cancer cells derived from the non-senescent state.

Cell death and differentiation·2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Professor Anthony Letai's research focuses on cancer cell death mechanisms.
  • His work has been pivotal in the development of targeted cancer therapies.

Discussion:

  • The interview highlights the significance of functional precision medicine in cancer treatment.
  • It explores the development and application of BH3 profiling for personalized cancer therapy.

Key Insights:

  • Letai's lab contributed to the FDA approval of Venetoclax for acute myeloid leukemia (AML).
  • BH3 profiling assay predicts cancer cell apoptosis, improving clinical outcomes.

Outlook:

  • The discussion emphasizes the importance of understanding cell death pathways for future cancer drug development.
  • Functional precision medicine and assays like BH3 profiling are key to advancing cancer care.